EG668525 Inhibitors
Chemical inhibitors of EG668525 include a range of compounds that target various signaling pathways, all of which converge on the regulation of this particular protein's activity. Wortmannin and LY294002, for instance, are both inhibitors of phosphatidylinositol 3-kinase (PI3K). By blocking the activity of PI3K, these inhibitors prevent the activation of AKT, a kinase that is a crucial component in the signaling cascade that leads to the activation of EG668525. Consequently, the inhibition of PI3K by Wortmannin and LY294002 results in a decrease in EG668525 activity due to reduced phosphorylation by AKT. Similarly, Rapamycin, by inhibiting the mammalian target of rapamycin (mTOR), impedes the downstream effects of the PI3K/AKT pathway, which includes the modulation of EG668525.
Further modulating the activity of EG668525 are inhibitors that act on the MAPK pathway. PD98059, SP600125, SB203580, and U0126 each target different kinases within this pathway, which is also implicated in the regulation of EG668525. PD98059 and U0126 specifically inhibit MEK1/2, leading to decreased activation of ERK and subsequent reduction in EG668525 activity. SP600125 and SB203580 target JNK and p38 MAP kinase, respectively, further contributing to the decrease in EG668525 function by impeding other branches of the MAPK pathway. Dasatinib and PP2, as broad-spectrum and more selective inhibitors of Src family tyrosine kinases, respectively, also play a role in the regulation of EG668525 activity. Src family kinases can activate several signaling pathways, and their inhibition by these chemicals leads to reduced activity of EG668525. Imatinib, while primarily known for its inhibition of BCR-ABL, c-KIT, and PDGFR kinases, can indirectly affect the signaling pathways that modulate EG668525 activity, though its primary targets are not directly linked to the regulation of EG668525. In addition to these, Y-27632 and Gefitinib can alter EG668525 activity by targeting the Rho/ROCK and EGFR signaling pathways. Y-27632 inhibits the Rho-associated protein kinase, which is part of the Rho/ROCK pathway, leading to diminished activation of downstream targets like EG668525. Gefitinib, by inhibiting EGFR tyrosine kinase, can decrease the signaling through various pathways that result in the activation of EG668525. Each of these inhibitors, through their respective targets, can contribute to the regulation of EG668525 activity in intricate signaling networks within the cell.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), which is upstream of AKT signaling pathway. EG668525 has been found to be a downstream target of the AKT pathway. Inhibition of PI3K by Wortmannin can prevent AKT activation, leading to reduced activity of downstream proteins such as EG668525. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K, functioning similarly to Wortmannin. It blocks the PI3K-dependent activation of AKT, thereby inhibiting subsequent phosphorylation and activation of proteins, including EG668525. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a key kinase in the PI3K/AKT pathway. By inhibiting mTOR, Rapamycin can decrease the activity of downstream proteins that are regulated by this pathway, which includes EG668525. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the mitogen-activated protein kinase (MAPK/ERK) pathway, specifically MEK. EG668525 is known to be regulated by the MAPK/ERK pathway, and inhibiting MEK with PD98059 leads to decreased function of downstream proteins such as EG668525. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which impacts the MAPK pathway. Inhibition of JNK can result in reduced activity of proteins that are modulated by this pathway, including EG668525. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, part of the MAPK pathway. By inhibiting p38, this chemical can reduce the function of proteins that are downstream in this signaling pathway, such as EG668525. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of the MEK1 and MEK2, which are upstream of ERK in the MAPK pathway. Inhibition of these kinases leads to reduced phosphorylation and activity of downstream proteins, including EG668525. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, notably of Src family kinases. Src kinases can influence several signaling pathways, including those that regulate the function of proteins like EG668525. By inhibiting Src kinases, Dasatinib can diminish the functional activity of EG668525. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases are involved in multiple signaling cascades that can regulate the activity of proteins like EG668525. Inhibiting these kinases with PP2 can result in decreased activation of EG668525. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that primarily targets BCR-ABL, c-KIT, and PDGFR. Given the complex crosstalk between tyrosine kinase pathways and other signaling cascades, inhibition by Imatinib can lead to decreased signaling through pathways that activate EG668525. | ||||||